LAPEC for the Treatment of Severe Constipation

Constipation Clinical Trial

Official title:

Laparoscopic-Assisted Percutaneous Endoscopic Cecostomy (LAPEC) in Adults for the Treatment of Severe Constipation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03909204
• Other study ID #: LAPEC for obstipation
• Status: Recruiting
• Phase: N/A
• Start date: May 20, 2019
• Est. completion date: May 12, 2023

Study information

• Verified date: October 2022
• Source: University Hospital Trnava
• Contact: Rastislav Hustak
• Phone: 00421918905728
• Email: rhustak[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Effective treatment for constipation is a real clinical challenge especially in patients with severe symptoms. Dietary measures (bulking agents) and drugs (laxatives, stool softeners, suppositories and enemas etc.) have limited efficacy in severe cases. If conservative measures do not help, surgical therapies might be considered. Subsequently, antegrade enemas through percutaneous colonic catheter were introduced as a less invasive option for treating severe constipation. The cecostomy has been performed laparoscopically, percutaneously, and with the laparoscopic-assisted percutaneous endoscopic cecostomy (LAPEC) technique. This approach allows patients to deliver osmotic agents to the right colon.The procedure has been demonstrated to be safe and effective in young adults and pediatrics. To date, there are only few studies evaluating the safety and efficacy of the LAPEC procedure in adults and all have retrospective profile. The aim of this prospective study is to compare short and long-term efficacy and safety of LAPEC in patients with severe constipation. Symptoms of defecation will be the main outcome criteria.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: May 12, 2023
• Est. primary completion date: May 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Refractory (> 6 months) and severe (based on a =KESS >11) and non-invasive therapeutic approaches, including an enhanced fiber diet, lifestyle changes, laxatives, and biofeedback failed.

• Slow transit constipation

• Anorectal malformation

• Mixed constipation (combination of outlet obstruction and slow transit)

• Hirschsprung's disease

• Idiopathic constipation ineffective to standard treatment

• Cauda equine syndrome

• Combination of spina bifida and tethered cord

• Colonic neuropathy.

• Persons 18 years or older at the time of signing the informed consent

• Signed informed consent

Exclusion Criteria:

• Non-LAPEC cecostomy procedure

• Pre-existing severe electrolyte imbalance

• Chronic high rectal tone

• Advanced liver cirrhosis (Child B or Child C)

• Pregnancy or puerperium

• Advanced colorectal cancer

• Presence of ventriculoperitoneal shunt

• Colonic disease or surgery that might impact safety of percutaneous colostomy tube placement (right hemicolectomy, IC resection, previous apendicostomy) and confirmed inflammatory bowel disease

• Any other condition, which in the opinion of the investigator would interfere with study requirements

Related Conditions & MeSH terms

• Cecostomy; Complications
• Constipation

Intervention

Procedure:
• LAPEC
Laparoscopic-Assisted Percutaneous Endoscopic Cecostomy: Initially, one to tree-laparoscopy port technique will be used, with hand placement of seroperitoneal sutures for cecal fixation. After than during colonoscopy a cecal position will be visualized and colonic lumen will be insuflated. After than the PEC tube will be introduced into the cecum using the dilators and sheath. Intravenous antibiotics will be given prior to the procedure and will continued parental temporary and later orally after catheter insertion. One weeks later, antegrade colonic enema will start during an out-patient visit including an educational training of the patient to the catheter manipulation. Antegrade enema solution will start at dose of 2ml/kg and will be increased up to 20ml/kg or a maximum dose of 2000 mL daily. Adjuvant of colonic motility stimulants are allowed during follow-up.

Locations

Country	Name	City	State
Slovakia	Rastislav Hustak	Trnava

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital Trnava

Country where clinical trial is conducted

Slovakia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Bowel QoL	Main outcome is the proportion of patients with treatment success at 3 and 6 months after the catheter placement. Treatment success is defined as a decrease of Quality of Life symptoms score at least 50% to a baseline values. To assess constipation severity the Knowles Eccersley Scott Symptom (KESS) before and throughout the study will be completed. The KESS is an 11-item tool for diagnosis of constipation. The KESS uses four- to five-point Likert scales that are scored on an unweighted linear integer scale. Total scores can range from 0 (no symptoms) to 39 (high symptom severity).	Exit data will be collected at 3 and 6 months after Intake data collection / PEC placement
Secondary	Change in Bowel QoL	Evolution of Quality of Life questionnaire before and after PEC placement at 3, 6, 12 and 24 months. To assess constipation severity the Knowles Eccersley Scott Symptom (KESS) before and throughout the study will be completed. The KESS is an 11-item tool for diagnosis of constipation. The KESS uses four- to five-point Likert scales that are scored on an unweighted linear integer scale. Total scores can range from 0 (no symptoms) to 39 (high symptom severity).	3 months, 6 months, 12 months, 24 months
Secondary	Removal rate	Proportion of patients with PEC in use and removed.	12 months
Secondary	Transit time	Change in x-ray transit time	At 3 and 12 month after PEC placement
Secondary	Frequency and Severity of Abdominal Pain	Frequency and severity of abdominal pain will be recorded daily and measured using the Visual analog pain scale as the appropriate visual analog scale. Score is based on self-reported measures of symptoms that are recorded with a single handwritten mark placed at one point along the length of a 10-points line that represents a continuum between the two ends of the scale-"no pain" on the left end (0) of the scale and the "worst pain" on the right end of the scale (10).	Data collection will start following consent and procedural training and will be collected daily from day 1 for the duration of the study, an expected average of 12 weeks
Secondary	Flush Administration Time	Administration time in minutes per flush will be defined as the time at which the tubing connected to the bag or syringe and the cecostomy fluid starts to infuse into the patient to the time the infusion is completed.	Data collection will start with the first flush administered following discharge from the hospital and will be collected with every subsequent flush through completion of the study, an expected average of 48 weeks
Secondary	Flush volume	Volume will be measured and recorded by the patient with each flush and calculated by the investigator in mL/kg using the weight obtained at the clinic visit preceding each effectiveness phase change.	Data collection will start with the first flush administered following discharge from the hospital and will be collected with every subsequent flush through completion of the study, an expected average of 48 weeks
Secondary	Procedural adverse event	Perioperative adverse events (complications)	1 month
Secondary	Long-term adverse events	Incidence rate of adverse events during follow-up	3, 6, 12, 24 months